Cart
sales@molnova.com
NRC-2694
CAS No. 936446-61-6
NRC-2694 ( —— )
Catalog No. M26774 CAS No. 936446-61-6
NRC-2694 is an antagonist of the epidermal growth factor receptor (EGFR). It has anti-cancer and anti-proliferative properties.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 295 | In Stock |
|
| 10MG | 507 | In Stock |
|
| 25MG | 802 | In Stock |
|
| 50MG | 1107 | In Stock |
|
| 100MG | 1503 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNRC-2694
-
NoteResearch use only, not for human use.
-
Brief DescriptionNRC-2694 is an antagonist of the epidermal growth factor receptor (EGFR). It has anti-cancer and anti-proliferative properties.
-
DescriptionNRC-2694 is an antagonist of the epidermal growth factor receptor (EGFR). It has anti-cancer and anti-proliferative properties.(In Vitro):NRC-2694 (80 ng) induce comparable inhibition of EGFR expression.(In Vivo):NRC-2694 (10 mg/kg) regresses the tumor in mice. The maximum tolerated dose of NRC-2694 in male and female mice is 2000 mg/kg (p.o.), in toxicity studies .
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorInfluenza virus
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number936446-61-6
-
Formula Weight418.5
-
Molecular FormulaC24H26N4O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCN1CCOCC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.J V Tuttle, et al. Purine 2'-deoxy-2'-fluororibosides as antiinfluenza virus agents. J Med Chem
molnova catalog
related products
-
Lazertinib
Lazertinib (YH25448, GNS-1480) is a highly potent, mutant-selective, irreversible, brain-penetrant and orally active EGFR tyrosine-kinase inhibitors for both the T790M mutation and activating EGFR mutations.
-
JBJ-04-125-02
JBJ-04-125-02 is a potent, mutant-selective, allosteric and orally active EGFR inhibitor with an IC50 of 0.26 nM for EGFRL858R/T790M. JBJ-04-125-02 can inhibit cancer cell proliferation and EGFRL858R/T790M/C797S signaling. JBJ-04-125-02 has anti-tumor activities.
-
TX1-85-1
TX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling.
